U.S. Markets open in 8 hrs 7 mins

The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan

Shanthi Rexaline

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peak

(Biotech stocks hitting 52-week highs on Dec. 17)

  • Endocyte, Inc. (NASDAQ: ECYT)

Down In The Dumps

(Biotech stocks hitting 52-week lows on Dec. 17)

  • Accelerate Diagnostics Inc (NASDAQ: AXDX)
  • Adamas Pharmaceuticals Inc (NASDAQ: ADMS)
  • Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP)
  • Aerie Pharmaceuticals Inc (NASDAQ: AERI)
  • Aileron Therapeutics Inc (NASDAQ: ALRN)
  • Applied DNA Sciences Inc (NASDAQ: APDN)
  • Applied Genetic Technologies Corp (NASDAQ: AGTC)
  • Aptevo Therapeutics Inc (NASDAQ: APVO)
  • Aquestive Therapeutics Inc (NASDAQ: AQST)
  • Aravive Inc (NASDAQ: ARAV)
  • Ardelyx Inc (NASDAQ: ARDX)
  • Assertio Therapeutics Inc (NASDAQ: ASRT)
  • aTyr Pharma Inc (NASDAQ: LIFE)
  • Avadel Pharmaceuticals PLC (NASDAQ: AVDL)
  • AzurRx BioPharma Inc (NASDAQ: AZRX)
  • Bioblast Pharma Ltd (NASDAQ: ORPN)
  • Biocept Inc (NASDAQ: BIOC)
  • BioXcel Therapeutics Inc (NASDAQ: BTAI)
  • BIOLASE Inc (NASDAQ: BIOL)
  • BIOLINERX LTD/S ADR (NASDAQ: BLRX)
  • Celldex Therapeutics, Inc. (NASDAQ: CLDX)
  • CELLECT BIOTECH/S ADR (NASDAQ: APOP)
  • Chimerix Inc (NASDAQ: CMRX)
  • Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)
  • CytRx Corporation (NASDAQ: CYTR)
  • Dare Bioscience Inc (NASDAQ: DARE)
  • Dova Pharmaceuticals Inc (NASDAQ: DOVA)
  • DURECT Corporation (NASDAQ: DRRX)
  • Edge Therapeutics Inc (NASDAQ: EDGE)
  • Evogene Ltd (NASDAQ: EVGN)
  • Enzo Biochem, Inc. (NYSE: ENZ)
  • Flexion Therapeutics Inc (NASDAQ: FLXN)
  • Forward Pharma A/S (NASDAQ: FWP)
  • Geron Corporation (NASDAQ: GERN)
  • Idera Pharmaceuticals Inc (NASDAQ: IDRA)
  • Intellia Therapeutics Inc (NASDAQ: NTLA)
  • Intra-Cellular Therapies Inc (NASDAQ: ITCI)
  • Kala Pharmaceuticals Inc (NASDAQ: KALA)
  • Kodiak Sciences Inc (NASDAQ: KOD)
  • Ligand Pharmaceuticals Inc. (NASDAQ: LGND)
  • Mersana Therapeutics Inc (NASDAQ: MRSN)
  • MOTIF BIO PLC/S ADR (NASDAQ: MTFB)
  • Mylan NV (NASDAQ: MYL)
  • Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV)
  • Nantkwest Inc (NASDAQ: NK)
  • Neon Therapeutics Inc (NASDAQ: NTGN)
  • Neovasc Inc (NASDAQ: NVCN)
  • Neurometrix Inc (NASDAQ: NURO)
  • Novan Inc (NASDAQ: NOVN)
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • Oncomed Pharmaceuticals Inc (NASDAQ: OMED)
  • Onconova Therapeutics Inc (NASDAQ: ONTX)
  • Ophthotech Corp (NASDAQ: OPHT)
  • Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP)
  • Paratek Pharmaceuticals Inc (NASDAQ: PRTK)
  • PLx Pharma Inc (NASDAQ: PLXP)
  • Precipio Inc (NASDAQ: PRPO)
  • Psychemedics Corp. (NASDAQ: PMD)
  • Reshape Lifesciences Inc (NASDAQ: RSLS)
  • Revance Therapeutics Inc (NASDAQ: RVNC)
  • Ritter Pharmaceuticals Inc (NASDAQ: RTTR)
  • Rockwell Medical Inc (NASDAQ: RMTI)
  • SCYNEXIS Inc (NASDAQ: SCYX)
  • Selecta Biosciences Inc (NASDAQ: SELB)
  • Sienna Biopharmaceuticals Inc (NASDAQ: SNNA)
  • Sierra Oncology Inc (NASDAQ: SRRA)
  • Soligenix, Inc. Common Stock (NASDAQ: SNGX)
  • Sophiris Bio Inc (NASDAQ: SPHS)
  • Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
  • Spero Therapeutics Inc (NASDAQ: SPRO)
  • Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS)
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
  • T2 Biosystems Inc (NASDAQ: TTOO)
  • Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH)
  • The Medicines Company (NASDAQ: MDCO)
  • TherapeuticsMD Inc (NASDAQ: TXMD)
  • Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP)
  • TRACON Pharmaceuticals Inc (NASDAQ: TCON)
  • Trinity Biotech plc (NASDAQ: TRIB)
  • TrovaGene Inc (NASDAQ: TROV)
  • Urovant Sciences Ltd (NASDAQ: UROV)
  • Vermillion, Inc. (NASDAQ: VRML)
  • Verrica Pharmaceuticals Inc (NASDAQ: VRCA)
  • Vital Therapies Inc (NASDAQ: VTL)
  • Viveve Medical Inc (NASDAQ: VIVE)
  • Voyager Therapeutics Inc (NASDAQ: VYGR)
  • Wright Medical Group NV (NASDAQ: WMGI)
  • Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)

See Also: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Stocks In Focus FibroGen Gets Chinese Approval For Drug to Treat Anemia Caused By Chronic Kidney Disease

FibroGen Inc (NASDAQ: FGEN) said its China unit has received marketing authorization from the National Medical Products Administration for Roxadustat, a hypoxia-inducible factor propyl hydroxylase inhibitor for treating patients with anemia caused by chronic kidney disease, who are dialysis dependent.

The stock rallied 15.41 percent to $45 in after-hours trading.

Puma's Breast Cancer Drug Produces Positive Results In a Late-stage Trial

Puma Biotechnology Inc (NASDAQ: PBYI) released top-line results from a late-stage study of its lead drug candidate PB272 being evaluated for HER2-positive metastatic breast cancer patients who have failed two or more prior lines of HER2-directed treatments. The study showed that PB272, or neratinib, in combination with capecitabine lead to a statistically significant improvement in centrally confirmed progression free survival, one of the coprimary endpoints. Although for the other coprimary endpoint of overall survival, the combo therapy did not achieve statistical significance, it trended positively in favor of the combo.

"The study was to be considered positive if either of the co-primary endpoints was positive," the company said.

The stock gained 11.58 percent to $23.90 in after-hours trading.

Achillion First-gen Factor D inhibitor Aces Mid-stage Trial

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) reported positive interim Phase 2 trials of its first-gen oral factor D inhibitor ACH-4471, as well as pharmacokinetics and potency data for its next-gen factor D inhibitors ACH-5228 and ACH-5548.

ACH-4471 is being evaluated for two indications, namely C3 glomerulopathy, or C3G, and paroxysmal nocturnal hemoglobinuria, or PNH. C3G leads to decline in kidney function over time, while PNH is a rare acquired blood disorder resulting in lethal hemolysis.

The company said it plans to enroll 20 patients in its 6- and 12-month trials for C3G and present data at an End-of-Phase 2 meeting in Q4 2019.

View more earnings on XBI

The stock moved up 7.50 percent to $2.58 in after-hours trading.

PhaseBio Appoints Pharma Industry Veteran to Board

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) said it has appointed former Pfizer Inc. (NYSE: PFE) executive Edmund Harrigan to its board, effective Dec. 13.

The stock fell 1.06 percent to $3.75 in after-hours trading.

Eyepoint, Rubius To Join Nasdaq Biotech Index

Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) and Rubius Therapeutics Inc (NASDAQ: RUBY) announced separately they will be added to the Nasdaq Biotechnology Index, effective Dec. 24.

Johnson & Johnson to Buyback $5B Worth of Shares; Reaffirms FY19 Guidance

Johnson & Johnson (NYSE: JNJ), which has been roiled in controversy over small amounts of carcinogenic asbestos found in its baby powder, announced a $5 billion stock buyback program.

The company also reaffirmed its full-year 2018 sales and adjusted EPS guidance of $81 billion-$81.4 billion, and $8.13-$8.18, respectively, which is in line with the current consensus estimate.

OptimizeRx Announces 2.1M Common Stock Offering

OptimizeRx Corporation (NASDAQ: OPRX) announced a proposed underwritten public offering of 2.1 million shares of its common stock by a selling shareholder.

The stock retreated 5.60 percent to $10.95 in after-hours trading.

Champions Oncology

Champions Oncology Inc (NASDAQ: CSBR) reported Q2 revenues of $6.7 million, up 28.6 percent year-over-year, and non-GAAP EPS of 3 cents compared to break-even results a year ago. Analysts, on average, estimated EPS of 3 cents. The company reiterated its 2019 guidance of 20 percent revenue growth and sustained quarterly operational profitability.

The stock fell 2.05 percent to $9.35 in after-hours trading.

Ligand In-licenses Drug to Treat Rare Skin Disorder

Ligand Pharmaceuticals Inc. (NASDAQ: LGND) said it has acquired economic rights to PTX-022 from Palvella Therapeutics for $10 million. PTX-022 is a novel topical formulation of rapamycin currently in Phase 2/3 development for the treatment of pachyonychia congenita, a rare skin disorder.

Ligand said it will not incur any development and commercialization expenses, but will receive a tiered royalty on net sales in the mid-to-upper single digits as well as regulatory and financing milestones.

On The Radar PDUFA Dates

ADMA Biologics Inc (NASDAQ: ADMA) awaits approval for its Prior Approval Supplement, or PAS, filing for Bivigam, which is an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency.

See more from Benzinga

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Millions of Barrels of Iranian Oil Are Piled Up in China's Ports
    Business
    Bloomberg

    Millions of Barrels of Iranian Oil Are Piled Up in China's Ports

    Two and a half months after the White House banned the purchase of Iran's oil, the nation's crude is continuing to be sent to China where it's being put into what's known as “bonded storage,” say people familiar with operations at several Chinese ports. This oil doesn't cross local customs or show up in the nation's import data and is not necessarily in breach of sanctions. The store of oil has the potential to push down global prices if Chinese refiners decide to draw on it, even as Organization of Petroleum Exporting Countries and allies curb production amid slowing growth in major economies.

  • Suze Orman says you need $5 million to retire — which is nonsense
    News
    MarketWatch

    Suze Orman says you need $5 million to retire — which is nonsense

    Author and personal-finance guru Suze Orman ruffled a lot of feathers in a recent podcast, saying that people need $5 million — maybe even $10 million — in order to retire. Orman was responding to a question about the “financial independence, retire early,” or “FIRE,” movement, a growing online trend in which people in their 30s or younger just stop working. Generally, these folks aim much lower — more like $1 million or so — then adjust their cost of living downward.

  • I’m engaged to a ‘money monster’ who racks up parking tickets and credit-card debt
    Business
    MarketWatch

    I’m engaged to a ‘money monster’ who racks up parking tickets and credit-card debt

    After getting engaged I found out about her debt, bad FICO score (FICO) excess parking tickets, etc. I educated and worked with her, and she eventually climbed out of it. Life is good, except she has new debt.

  • 3 Terrible Reasons to Sell Canopy Growth
    Business
    Motley Fool

    3 Terrible Reasons to Sell Canopy Growth

    Canopy Growth (NYSE: CGC) quickly went from being a favorite cannabis stock for many investors to a favorite stock to bash. With Canopy Growth founder and longtime CEO Bruce Linton getting pushed out earlier this month, some investors are probably wondering if it's time to throw in the towel on the stock. Sure, Canopy Growth's share price has plunged nearly 30% since the beginning of May. But selling because of this drop is one of the worst reasons you could possibly come up with.

  • Business
    Barrons.com

    Expect a 10% Market Correction Within 3 Months, Morgan Stanley CIO Says

    As much of the U.S. faces a heat wave, the appetite for stocks is just as sizzling after Fed Vice Chairman Richard Clarida and New York Fed President John Williams revved up market expectations about rate cuts. Hold your horses, says Mike Wilson, chief investment officer of Morgan Stanley, who tells MarketWatch in an interview that investors should wait for better times to jump into this stock market. “We're not looking for the bottom to fall out like last year, but I do expect a 10% correction in the next three months,” said Wilson, whose end-year S&P 500 target is 2,750.

  • Boeing stock rallies after aircraft maker puts a price tag on 737 Max debacle
    Business
    MarketWatch

    Boeing stock rallies after aircraft maker puts a price tag on 737 Max debacle

    Boeing Co. stock rose to its highest level in nearly a month on Friday after Wall Street breathed a collective sigh of relief as the aircraft maker put a relatively paltry price on the problems facing its 737 Max aircraft. Boeing (BA) late Thursday said it expected a $5.6 billion hit in second-quarter revenue and pre-tax earnings. It also disclosed a $1.7 billion increase in costs to produce the aircraft. Shares rose more than 3%, putting them on pace for their biggest one-day percentage increase since June 18 and on track for their highest close since June 26.

  • 3 Reasons for Netflix Investors to Worry After the Latest Report
    Business
    Motley Fool

    3 Reasons for Netflix Investors to Worry After the Latest Report

    Good content may not be enough Management blamed the usual suspects in the earnings release, noting that its record first-quarter additions of 9.6 million members may have pulled some second-quarter subscribers forward, and also pointed a finger at the quarter's content slate, which it said drove fewer subscriber additions than anticipated. That excuse seems a little feeble, considering the company had a number of seemingly strong releases in the period. Dead to Me, a dramedy starring Christina Applegate, attracted 30 million households in its first four weeks.

  • Amarin: Is a Buyout Really Off the Table?
    Business
    Motley Fool

    Amarin: Is a Buyout Really Off the Table?

    Amarin (NASDAQ: AMRN) drew the ire of its shareholders last week by rolling out a breathtaking $460 million capital raise. First up, the biopharma recently announced that sales of its prescription omega-3 treatment, Vascepa, have been going strong ever since the drug showed a 25% relative risk reduction in terms of serious cardiovascular events in the outcomes trial known as Reduce-It. Amarin, in turn, reported that its cash position stood at a healthy $221 million at the end of June, thanks to Vascepa's strong sales trajectory.

  • President Trump's 2020 Campaign Is Now Selling Plastic Straws: 'Liberal Paper Straws Don't Work'
    News
    Meredith Videos

    President Trump's 2020 Campaign Is Now Selling Plastic Straws: 'Liberal Paper Straws Don't Work'

    President Donald Trump's 2020 campaign store sells “Make America Great Again” hats, T-shirts, cups, towels and even dog leashes. But one of its newest items might be one of the campaign's biggest attempt to troll: Trump-branded plastic straws.

  • How Bad Will Harley-Davidson's Q2 Report Be?
    Business
    Motley Fool

    How Bad Will Harley-Davidson's Q2 Report Be?

    When Harley-Davidson (NYSE: HOG) reports on its second quarter  Tuesday, we can expect to see more of the same on the domestic front. Harley is unleashing its all-electric LiveWire motorcycle on the market next month, and it has advanced plans to build smaller motorcycles for foreign markets over the next two years. The Pan American 1250 is one of the mid-size motorcycles Harley-Davidson will be producing.

  • 3 Stocks to Buy and Hold for Decades
    Business
    Motley Fool

    3 Stocks to Buy and Hold for Decades

    What really gets me excited about Lockheed Martin stock for the long term, though, is the company's far-thinking research into a new form of clean energy -- cold fusion -- coupled with the knowledge that this $100 billion company has the financial resources to make a serious attempt at the project. I first started writing about Lockheed's cold fusion aspirations five years ago, when Lockheed said it hoped to have a working cold fusion reactor inside of a decade. Here at the halfway mark, Lockheed just confirmed that it's on its fourth iteration of a test reactor at Skunk Works -- and very close to halfway toward its goal.

  • AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout
    Business
    Motley Fool

    AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout

    AbbVie (NYSE: ABBV) announced in June that it plans to acquire Allergan (NYSE: AGN). Could the company's previous deals provide some insight into how adept AbbVie's team has been at identifying the real value of potential acquisition targets? With this in mind, I developed a report card of AbbVie's acquisitions to identify the possible implications for the Allergan deal.

  • AT&T earnings: Expect another quarter of big video losses
    Business
    MarketWatch

    AT&T earnings: Expect another quarter of big video losses

    As approval for T-Mobile US Inc.'s deal with Sprint Corp. looms over the wireless industry, fellow carrier AT&T Inc. (T) will show of the impact of its own mega-deal when the company reports second-quarter results next Wednesday before the opening bell. Earnings: Analysts surveyed by FactSet project that AT&T earned 89 cents a share on an adjusted basis, down from 91 cents a year earlier. Revenue: The FactSet consensus models $44.9 billion in June-quarter revenue for AT&T, while the Estimize consensus calls for $45.1 billion.

  • 7 Things You Didn't Know About NIO
    Business
    Motley Fool

    7 Things You Didn't Know About NIO

    Hitting the road Raising $1 billion during its initial public offering, NIO debuted as a publicly traded company on the American market in September 2018. According to Reuters, management had higher hopes for the IPO; a source close to the issue claimed that the company had sought a valuation as much as three times higher when it first began the IPO process. On its first day of trading, the stock opened at $6, closed at $6.60, and traded as high as $6.93 for a reasonable pop.

  • Wanna Bet $1.3 Trillion on Chinese Regulators?
    Business
    Bloomberg

    Wanna Bet $1.3 Trillion on Chinese Regulators?

    In fact, the country's largest search and e-commerce provider(1)is ultimately controlled by Alibaba Partnership, a collection of 38 people, most of whom hold senior positions in the company. This business structure, called a variable-interest entity, became common among Chinese companies because Beijing restricts foreign investment in certain sectors, such as the internet. It also enables firms to raise money abroad and lets early investors get their funds out of the country. Tencent Holdings Ltd., Meituan Dianping and Baidu Inc. all hew to various versions of the VIE, allowing them to exploit a gap in Chinese law.

  • Business
    Oilprice.com

    U.S. Shale Is Doomed No Matter What They Do

    With financial stress setting in for U.S. shale companies, some are trying to drill their way out of the problem, while others are hoping to boost profitability by cutting costs and implementing spending restraint. “Turbulence and desperation are roiling the struggling fracking industry,” Kathy Hipple and Tom Sanzillo wrote in a note for the Institute for Energy Economics and Financial Analysis (IEEFA). A corporate struggle over control of the company reached a conclusion recently, with the Toby and Derek Rice seizing power.

  • Black Georgia Lawmaker Alleges White Man Told Her to 'Go Back Where You Came From' in Grocery Store Confrontation
    U.S.
    Meredith Videos

    Black Georgia Lawmaker Alleges White Man Told Her to 'Go Back Where You Came From' in Grocery Store Confrontation

    A black lawmaker in Georgia says a white man verbally harassed her and told her to “go back where you came from” during a confrontation at a Publix grocery store on Friday.

  • 3 Stocks I'm Never Selling
    Business
    Motley Fool

    3 Stocks I'm Never Selling

    Here's why Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), Walt Disney (NYSE: DIS), and Intuitive Surgical (NASDAQ: ISRG) belong in that category. Alphabet claims eight products that each have more than 1 billion users every month. The world's biggest company right now, Microsoft, tried to challenge Alphabet's Google Search by launching its own Bing search engine several years ago.

  • The Absurdity of Aurora Cannabis' Latest Analyst Downgrade
    Business
    Motley Fool

    The Absurdity of Aurora Cannabis' Latest Analyst Downgrade

    But Carey recently downgraded Aurora to neutral only three months after initiating coverage on the stock with a buy recommendation. Wall Street analysts change their views on stocks all of the time, of course. But this latest downgrade for Aurora illustrates the absurdity of giving too much weight to analysts' recommendations.

  • 2 Southwest planes out of service after Nashville collision
    Finance
    American City Business Journals

    2 Southwest planes out of service after Nashville collision

    Two Southwest Airlines aircraft are out of service after the pair collided with one another Saturday night on the Nashville International Airport tarmac. One flight bound for Atlanta and one for St. Louis were backing up Saturday night when the two collided, a Southwest Airlines Co. (NYSE: LUV) spokesperson told CNN. The collision appeared to knock the 'S' off the winglet of one aircraft, according to a Twitter user.

  • Iranian hostilities could cause spike in global oil prices
    World
    Autoblog

    Iranian hostilities could cause spike in global oil prices

    Seizures of oil tankers and other hostile Iranian measures in the Strait of Hormuz are already raising insurance rates for shipping companies and could eventually reduce tanker traffic in the vital waterway, with a spike in global oil prices a serious risk even without war, energy and maritime experts say. On Friday, Iran seized a British-flagged oil tanker in the narrow passageway that carries one-fifth of the world's crude exports and a second Liberian-flagged ship was briefly detained. "If this kind of problem continues, you might see people start to shy away from the (Persian) Gulf or try to reflag — not be a British tanker," said energy economist Michael Lynch.

  • The TD Ameritrade Holding (NASDAQ:AMTD) Share Price Has Gained 69% And Shareholders Are Hoping For More
    Business
    Simply Wall St.

    The TD Ameritrade Holding (NASDAQ:AMTD) Share Price Has Gained 69% And Shareholders Are Hoping For More

    Just take a look at TD Ameritrade Holding Corporation (NASDAQ:AMTD), which is up 69%, over three years, soundly beating the market return of 35% (not including dividends). There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). TD Ameritrade Holding was able to grow its EPS at 32% per year over three years, sending the share price higher.

  • Better Buy: Scotts Miracle-Gro vs. ConocoPhillips
    Business
    Motley Fool

    Better Buy: Scotts Miracle-Gro vs. ConocoPhillips

    At first blush, it doesn't seem like comparing lawn care company Scotts Miracle-Gro (NYSE: SMG) to oil driller ConocoPhillips (NYSE: COP) would make much sense. But if you step back and look at the bigger picture, the two companies are actually in the middle of big bets on growth. How these plans pan out will have a big impact on each company's future.

  • Chesapeake Energy’s stock falls to 20-year low, Kinder Morgan’s drops after earnings
    Business
    MarketWatch

    Chesapeake Energy’s stock falls to 20-year low, Kinder Morgan’s drops after earnings

    Shares of Kinder Morgan Inc. dropped Thursday in active trading, dragged down by a disappointing earnings report and a selloff in crude oil and natural gas prices. The weakness in oil and gas prices also helped fuel an early selloff in energy stocks, before they bounced later in the session, while Chesapeake Energy Corp. shares (CHK) tumbled on heavy volume to close at a 20-year low. The SPDR Energy Select Sector exchange-traded fund (XLE) fell as much as 1.1% in intraday trading, before bouncing to close up less than 0.1% amid a rally in the broader stock market.

  • 3 Top Augmented-Reality Stocks to Buy Right Now
    Business
    Motley Fool

    3 Top Augmented-Reality Stocks to Buy Right Now

    The company's HoloLens device is the market leader in applications created for enterprise augmented reality -- or "mixed reality," in Microsoft's parlance. If you're an astute tech investor, you may have recoiled when the words "Microsoft" and "device" are mentioned in the same breath. Here's why it's different for AR: Microsoft is focused on enterprise (business) applications, which allows it to seamlessly transition to the company's suite of business applications while minimizing the app and developer weaknesses that have hampered its consumer-focused mobile device offerings.